Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Aleix Prat(Hospital Clínic de Barcelona), Ana Vivancos(Vall d'Hebron Institute of Oncology), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Youli Xia(University of North Carolina at Chapel Hill), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Eudald Felip(University of Ioannina), Judit Matito(Oryzon Genomics (Spain)), Meritxell Bellet(Vall d'Hebron Hospital Universitari), Anna Suñol(Universitat Autònoma de Barcelona), Blanca González‐Farré(Hospital Clínic de Barcelona), Marina Gómez-Rey(Vall d'Hebron Institute of Oncology), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Joel S. Parker(University of North Carolina at Chapel Hill), Mireia Margelí Vila(Institut Català d'Oncologia), Patricia Galván(Vall d'Hebron Institute of Oncology), Charles M. Perou(University of North Carolina at Chapel Hill), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Esther Sanfeliu(Hospital Clínic de Barcelona), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Núria Chic(Breast Cancer Research Foundation), Eva Ciruelos(Hospital Universitario 12 De Octubre), Patricia Villagrasa, Cristina Saura(Vall d'Hebron Hospital Universitari), Mercedes Marín‐Aguilera(Oryzon Genomics (Spain)), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ester Ballana(IrsiCaixa), María Vidal(Inserm), Anna Belén Rodríguez(Hospital Clínic de Barcelona), Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 65
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k